Company
Hua Medicine
Headquarters: Shanghai, China
Employees: 146
CEO: Dr. Li Chen Ph.D.
Market Cap
HK$2.31 Billion
HKD as of Jan. 1, 2024
US$295.8 Million
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes. The company also offers Dorzagliatin in combination with Metformin that is in Phase I clinical trial. In addition, it provides Dorzagliatin in combination with Sitagliptin, Empagli, Pioglitazone, and Insulin for the treatment of Type 2 diabetes that is in pre-clinical stage. Further, the company is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia or PD-LID. The company was incorporated in 2011 and is headquartered in Shanghai, China.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Hua Medicine has the following listings and related stock indices.
Stock: HKEX: 2552 wb_incandescent